Engineering photodynamics for treatment, priming and imaging
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Photodynamic therapy (PDT) is a photochemistry-based treatment approach that relies on the activation of photosensitizers by light to locally generate reactive oxygen species that induce cellular cytotoxicity, in particular for the treatment of tumours. The cytotoxic effects of PDT are depth-limited owing to light penetration limits in tissue. However, photodynamic priming (PDP), which inherently occurs during PDT, can prime the tissue microenvironment to adjuvant therapies beyond the direct PDT ablative zone. In this Review, we discuss the underlying mechanisms of PDT and PDP, and their application to the treatment of cancer, outlining how PDP can permeabilize the tumour vasculature, overcome biological barriers, modulate multidrug resistance, enhance immune responses, increase tumour permeability and enable the photochemical release of drugs. We further examine the molecular engineering of photosensitizers to improve their pharmacodynamic and pharmacokinetic properties, increase their molecular specificity and allow image guidance of PDT, and investigate engineered cellular models for the design and optimization of PDT and PDP. Finally, we discuss alternative activation sources, including ultrasound, X-rays and self-illuminating compounds, and outline key barriers to the clinical translation of PDT and PDP. Photodynamic therapy allows the local destruction of diseased cells and tissues by light. This Review examines how photodynamic therapy and priming can be engineered for the treatment of localized, regional and distant cancer, from photosensitizer engineering to photonic devices and clinical translation. Photodynamic therapy (PDT), including photodynamic priming, allows the localized destruction of diseased cells and tissues by light, benefitting from minimal side effects, minimally invasive administration and the potential for combination therapies. Nanomaterials can be designed to enable controlled delivery of combination therapies, improve the pharmacokinetics of photosensitizers and enable optical imaging-guided PDT. PDT can be applied for tumour ablation, modulation of the tumour environment and boosting of the immune responses against local and metastatic disease. Robust clinical trials, industry involvement and collaboration between different research fields (such as, physics, mathematics, chemistry and engineering) are essential for the clinical translation of PDT-based therapies. Photodynamic therapy (PDT), including photodynamic priming, allows the localized destruction of diseased cells and tissues by light, benefitting from minimal side effects, minimally invasive administration and the potential for combination therapies. Nanomaterials can be designed to enable controlled delivery of combination therapies, improve the pharmacokinetics of photosensitizers and enable optical imaging-guided PDT. PDT can be applied for tumour ablation, modulation of the tumour environment and boosting of the immune responses against local and metastatic disease. Robust clinical trials, industry involvement and collaboration between different research fields (such as, physics, mathematics, chemistry and engineering) are essential for the clinical translation of PDT-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Hofer, M., & Lutolf, M. P. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00279-y · Cited by 1,184 · cited 1×
“The heterogeneity of models and the absence of functional assays are major challenges in the utilization of 3D cancer models for evaluating treatment effects 103,104 .”
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082 · cited 1×
“The heterogeneity of models and the absence of functional assays are major challenges in the utilization of 3D cancer models for evaluating treatment effects 103,104 .”
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561 · cited 1×
“Most water-soluble agents, proteins and nanoparticles, including therapeutic and immunologic agents, are internalized by cancer cells through endocytosis and are frequently sequestered in the endolysosomes.”
Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla, T., Hitre, E., Hammel, P., Hendifar, A. E., Bates, S. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00590 · Cited by 499
Cancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening?
Shah, S. C., Kayamba, V., Peek, R. M., & Heimburger, D. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00200 · Cited by 382
Phan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269 · cited 1×
“…the use of animals in research and better recapitulate human conditions, compared with 2D culture models 99 , 3D human cell culture models can be engineered that mimic the complexity of cancer tissues and offer the investigational accessibility and throughput of in vitro models 100–102 (Fig.”
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234 · cited 1×
“Under fluid flow, human ovarian cancer microtumours undergo epithelial-to-mesenchymal transition 115 , which induces carboplatin resistance but improves the cellular delivery of photosensitizers formulations and increases photoimmunotherapy efficacy 116,117 .”
Self-citationSchipmann, S., Müther, M., Stögbauer, L., Zimmer, S., Brokinkel, B., Holling, M., Grauer, O., Suero Molina, E., Warneke, N., & Stummer, W. (2021) · Journal of Neurosurgery · doi:10.3171/2019.11.jns192443 · Cited by 121 · cited 1×
“Larger controlled clinical trials of PDT should thus be guided and informed by an organized framework, equivalent to the Radiation Therapy Oncology Group, to clarify its clinical implementation, establish guidelines for dosimetry and treatment design, and allow for appropriate comparisons with…”
Metadata
- Authors
- Obaid, G., Celli, J. P., Broekgaarden, M., Bulin, A.-L., Uusimaa, P., Pogue, B., Hasan, T., & Huang, H.-C.
- Venue
- Nature Reviews Bioengineering
- Published
- 2024-06-19
- Volume
- 2
- Issue
- 9
- Pages
- 752-769
- ISSN
- 2731-6092 (ISSN-L)
- OpenAlex
- W4399807124
- Cited by
- 206
- References
- 11
- FWCI
- 24.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineering photodynamics for treatment, priming and imaging. https://app.cochat.ai/papers/10.1038/s44222-024-00196-z
- The paper
- Obaid, G., Celli, J. P., Broekgaarden, M., Bulin, A.-L., Uusimaa, P., Pogue, B., Hasan, T., & Huang, H.-C. (2024). Engineering photodynamics for treatment, priming and imaging. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-024-00196-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.